Next Article in Journal
Long-Term Growth Hormone Treatment of Children with PWS: The Earlier the Start, the Better the Outcomes?
Previous Article in Journal
Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
 
 
Comment
Peer-Review Record

Comment on Pata et al. Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes. J. Clin. Med. 2022, 11, 218

J. Clin. Med. 2022, 11(9), 2495; https://doi.org/10.3390/jcm11092495
by Johannes Jongen *, Jessica Schneider, Volker Kahlke and Tilman Laubert
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2022, 11(9), 2495; https://doi.org/10.3390/jcm11092495
Submission received: 13 February 2022 / Accepted: 25 April 2022 / Published: 29 April 2022

Round 1

Reviewer 1 Report

The comment is appropriate. The requests for clarification are legitimate considering the previous publications of 1985. In particolar, these two articols reported the same tecnique that Pata et al. describe as new, therefore the comment is fitting.    

English language and style not require changes.

 

Reviewer 2 Report

This is a letter to the editor about the article by Pata F et al. "Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes", published in the special issue " Colorectal Surgery: Latest Advances and Prospects".doi: 10.3390/jcm11010218.

All points raised in the letter sound reasonable, but should be published with a mandatory reply by authors of the original article to give a complete overview to the readers. 

Back to TopTop